NCT06946433

Brief Summary

The goal of this clinical trial is to learn about the safety and tolerability of transcranial direct current stimulation (tDCS) combined with cognitive training in adults with Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD). The main question it aims to answer is: Is tDCS safe and well-tolerated in adults with ASD and/or ADHD? Researchers will compare active tDCS to a sham (placebo-like) stimulation to evaluate safety and tolerability. Participants will: Receive either active or sham tDCS for 20 minutes daily over 10 consecutive workdays Undergo stimulation with the anode placed at F3 and the cathode at Fp2 Complete daily cognitive training exercises using the NeuronUP platform during stimulation Attend baseline and follow-up assessments to monitor for any side effects or discomfort related to the intervention

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 7, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 19, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 19, 2024

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 8, 2025

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 27, 2025

Completed
Last Updated

August 1, 2025

Status Verified

July 1, 2025

Enrollment Period

1.2 years

First QC Date

April 8, 2025

Last Update Submit

July 29, 2025

Conditions

Keywords

tdcsautismadhd

Outcome Measures

Primary Outcomes (1)

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Participants will be monitored for adverse events, side effects (e.g., headache, skin irritation, fatigue), and dropout rates. This will be assessed through participant self-report, clinician observation, and standardized side effect checklists administered during and after each session. The outcome will help determine whether daily tDCS paired with cognitive training is safe and acceptable for adults with ASD and/or ADHD.

    Throughout the 10-day intervention period and at follow-up (up to 2 weeks post-intervention)

Study Arms (2)

Active tDCS + Cognitive Training

ACTIVE COMPARATOR

Participants in this arm will receive anodal transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes per session over 10 consecutive workdays. The anode will be placed over the left dorsolateral prefrontal cortex (F3) and the cathode over the right frontopolar cortex (Fp2) using the 10-20 EEG system. Stimulation will be administered concurrently with cognitive training using the NeuronUP platform, which includes tasks targeting attention, memory, and executive function.

Device: Transcranial Direct Current Stimulation - ActiveBehavioral: Cognitive Training

Sham tDCS + Cognitive Training

SHAM COMPARATOR

Participants in this arm will undergo the same setup and procedures as the active tDCS group but will receive sham stimulation, which mimics the sensation of tDCS without delivering current beyond the initial ramp-up/down. They will also complete cognitive training with the NeuronUP platform during each session.

Device: Transcranial Direct Current Stimulation - ShamBehavioral: Cognitive Training

Interventions

This intervention involves non-invasive brain stimulation using transcranial direct current stimulation (tDCS) delivered via saline-soaked sponge electrodes. The anode is placed at F3 (left dorsolateral prefrontal cortex) and the cathode at Fp2 (right frontopolar cortex), according to the international 10-20 EEG system. A 2 mA current is applied for 20 minutes per session, administered once daily on 10 consecutive workdays. During stimulation, participants engage in cognitive training using the NeuronUP platform, which provides structured, interactive tasks designed to train executive function, attention, and working memory. This combination aims to enhance neural plasticity by pairing neuromodulation with cognitive engagement.

Active tDCS + Cognitive Training

The sham condition mimics the active setup but delivers only brief ramp-up/down stimulation, producing the initial sensation without sustained current.

Sham tDCS + Cognitive Training

The cognitive training intervention in this study is delivered through NeuronUP, a digital platform offering evidence-based cognitive stimulation activities. This intervention targets core cognitive domains such as working memory, attention, and executive function through personalized, interactive tasks. What distinguishes this approach is NeuronUP's extensive library of over 10,000 activities, its ability to tailor difficulty levels in real time based on individual performance, and the inclusion of functional tasks that mirror real-life scenarios. Unlike other interventions, NeuronUP also enables therapist-guided customization, allowing for individualized treatment plans that evolve with participant progress, ensuring both relevance and ecological validity.

Active tDCS + Cognitive TrainingSham tDCS + Cognitive Training

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18 to 55 years
  • Clinical diagnosis of Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed via medical records or structured clinical interview
  • Able to provide informed consent
  • Fluent in the language used for assessments and cognitive training tasks
  • Stable medication regimen (if applicable) for at least 4 weeks prior to enrollment
  • Willing and able to attend 10 consecutive weekday sessions and follow-up assessment

You may not qualify if:

  • History of epilepsy, seizures, or significant neurological disorder (e.g., traumatic brain injury, stroke)
  • Current diagnosis of psychotic disorder or bipolar disorder
  • Presence of metal implants in the head (excluding dental work), pacemaker, or other contraindications to tDCS
  • Current substance use disorder (within past 6 months)
  • Pregnant or planning to become pregnant during the study period
  • Participation in another intervention study within the last 30 days
  • Any condition that, in the opinion of the investigators, may make participation unsafe or interfere with study procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona, 08035, Spain

Location

MeSH Terms

Conditions

Autism Spectrum DisorderAttention Deficit Disorder with HyperactivityAutistic Disorder

Interventions

Cognitive Training

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental DisordersAttention Deficit and Disruptive Behavior Disorders

Intervention Hierarchy (Ancestors)

Neurological RehabilitationRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and Services

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 8, 2025

First Posted

April 27, 2025

Study Start

November 7, 2022

Primary Completion

January 19, 2024

Study Completion

January 19, 2024

Last Updated

August 1, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations